The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

The Potentiation of Checkpoint Blockade With Oncolytic Virus

James P. Allison, PhD
Published Online: 4:45 PM, Wed June 4, 2014
James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, discusses the potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus.

<<< Back to "Immunotherapy News from ASCO"

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.